---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045807"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:18:35.339879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac

## Summary
- Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.
- Caldolor associated with 45% reduction in renal dysfunction (p<0.001) and 78% fewer hematuria events.
- In pediatric patients, Caldolor showed 51-65% lower rate of adverse drug reactions.
- Caldolor also linked to decreased ER visits and shorter hospital stay for both adults and children.

## SEC filing metadata
- accession: 0001628280-24-045807
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/0001628280-24-045807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/cpix-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045807
- JSON: https://secwatch.observer/filing/0001628280-24-045807.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.